Definitely getting mixed messages. Lanza's quote here from the Bioworld article sums up my thinking process regarding the use of hESC for this project:
"I'm still very optimistic that this can be solved," Lanza said. "But in the meantime, you've got to move ahead with what you've got."
From the context of the article, he is clearly talking about moving ahead with hESC.
With the 400,000+ embryos in these IVF clinics, surely there are some that are type O-. Plus whatever lines CHA has access to. I guess it is just luck of the draw as far as what type you end up with.
Again, I worry that I am jumping to conclusions or being overly optimistic, but I think it is possible that Lanza/SCRMI are quite far along on the universal blood program using hESC.
If this were true, it would explain the extreme secrecy regarding any information in this area. This project would easily be worth billions.
Furthermore, and this is an even bigger stretch.. Rocky, please tell me if you think the following is a bunch of crap.
If ACT is this close to universal blood with hESC, I can justify Caldwell getting 10-20% of the company, which otherwise I can not find justification for. Perhaps, similar to those offshore accounts (which I admittedly do not understand very well) getting all of those shares for pennies that caused the defaults. This is almost entirely speculation on my part, but it is the only explanation I can find that doesn't make Caldwell look terrible.
Or the simpler solution, I am extrapolating all of this, and Caldwell simply robbed us blind.
The "secrecy" here could also be explained by the simple fact that maybe they haven't solved the problem yet, and results are still a few years away.
Unfortunately, I think it is most likely that we were robbed, and universal blood is still a work in progress.
Market Data 
Markets 
AI
